Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
HER2 overexpression promotes EMT and the emergence of cancer stem cell properties in BC.
|
28445439 |
2017 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Taken together, ERBB2 is required for the dysregulation of cancer-related genes, such as <i>MED24</i>, during lung tumor development.
|
31248101 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our data reveal a mechanism for HER2/neu-induced cancer cell invasion via miRNA deregulation.
|
19419954 |
2009 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The results of in situ hybridization using a 32P-labeled neu/erbB-2 RNA probe performed on four WHO grade I and II astrocytomas, seven WHO grade IV glioblastomas, one WHO grade II oligoastrocytoma, one WHO grade III anaplastic astrocytoma, and three WHO grade I meningiomas were consistent with these immunomorphological data, and Northern blot analysis also indicated an overexpression of neu/c-erbB-2 mRNA in gliomas of different grades of malignancy and in meningiomas.
|
7914508 |
1994 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Clinicopathological parameters and molecular tests such as EndoPredict(®) (EPclin) can support decision making in patients with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative cancer.
|
25404424 |
2015 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Overexpression of neu (also known as c-erbB-2 or HER-2) commonly occurs in human cancer and is also known to enchance tumor metastasis and chemoresistance.
|
9150363 |
1997 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Twenty-three UUTUC (13.5%) were determined as HER2-positive cancer according to ASCO/CAP and ToGA criteria.
|
24551292 |
2014 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These preclinical results support the clinical evaluation of HDAC inhibitors against ErbB2-overexpressing malignancies, and further indicate that encapsulation into targeted and nontargeted liposomes substantially improves the in vivo pharmacokinetics, tumor uptake, and antitumor properties of hydroxamate-based HDAC inhibitors.
|
15867240 |
2005 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Using HER2-positive BCBMs as a case study, we highlight recent data from orthotopic brain metastasis models that implicate brain-specific drug resistance mechanisms in BCBMs and suggest a translational research paradigm to guide drug development for treatment of BCBMs.<i>Clin Cancer Res; 24(8); 1795-804.©2018 AACR</i>.
|
29437794 |
2018 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The HER-2/neu gene was found both in normal ovaries and malignant tumors, without any apparent difference among the various histological types.
|
1349908 |
1992 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The HER-2 (also known as ErbB2/c-erbB2/HER-2/neu) oncogene is the most frequently amplified oncogene in breast cancer and is also commonly amplified in other forms of cancer.
|
14632727 |
2003 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
As BTK-C and HER2 are often coexpressed in human breast cancers, these observations indicate that BTK-C is a potential therapeutic target and that ibrutinib could be an effective drug especially for HER2(+) breast cancer.Mol Cancer Ther; 15(9); 2198-208.©2016 AACR.
|
27256378 |
2016 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
However, the molecular association of HER2 gene mutation with HER2 gene amplification and/or protein expression in cancer tissues has not been clearly defined.
|
29504811 |
2018 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Detected alterations comprised chromosomal copy number changes and rearrangements, including amplification of cancer driver genes such as ERBB2 and CDK6.
|
23197571 |
2012 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Overexpression of the transmembrane tyrosine kinases Her2 and EGFR is associated with aggressive malignancies, and several therapeutic strategies targeting the two receptors are now in various stages of clinical development.
|
12890536 |
2003 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We found that initial disease symptoms and signs, mammographic calcification, tumor site, number of positive axillary lymph nodes (ALNs), American Joint Committee on Cancer pT stage, and human epidermal growth factor receptor 2 status were associated with IMLN metastasis (all P < .05).
|
29995764 |
2018 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The expression of p53, c-erbB2, Ki-67, estrogen receptor (ER) and progesterone receptor (PR) in cancer tissue was detected by immunohistochemical staining.
|
17915203 |
2007 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These data suggest that 11p14 allelic loss plays a role in the evolution of human breast cancer, amplification of c-erbB-2 gene is associated with increasing stage of malignancy, and alteration of the c-myc gene in inflammatory breast carcinoma may contribute to the rapid progression of this human tumor subtype.
|
2573420 |
1989 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Being responsible for the development of many cancer types, EGFR (Epidermal Growth Factor Receptor) and HER2 (Human Epidermal growth factor Receptor 2) were the focus of this study where a series of novel 4-anilino-furo[2,3-d]pyrimidine derivatives was designed, synthesized and biologically evaluated.
|
29275232 |
2018 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
ECD_Apt1 could be an effective low-cost alternative to conventional anti-Her2 antibody in solid phase immunoassays for cancer diagnosis and related applications.
|
28224267 |
2017 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
HER2 has been linked to CSLCs in breast cancers and, therefore, we wanted to assess whether HER2 has a role in CSLCs in ALK translocated cancers.
|
28656214 |
2017 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Graphical abstract Schematic presentation of amplified imaging of human epidermal growth factor receptor 2 (HER2) dimerization on cancer cell surfaces by using a co-localization triggered DNA nanoassembly (CtDNA).
|
31197538 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The ErbB1 and ErbB2 receptors are oncogenes with therapeutic significance in human cancer, whereas the transforming potential of the related ErbB4 receptor has remained controversial.
|
16251361 |
2006 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In summary, our group A cases account for 1.5% of breast cancers, and 10.7% of all HER2/neu-amplified cancers classified as such based on 2013 ASCO/CAP criteria.
|
30121371 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
HER2-amplified gastric and gastroesophageal junction cancer cell lines were highly sensitive to lapatinib.
|
24112719 |
2013 |